Von Willebrand factor binding to heparin in various types of von Willebrand disease

Hematology Journal

Volumn 1, Issue 3, 2000, Pages 190-198

  Rastegar Lari, Ghassem ^a   Legendre, Paulette ^a   Ajzenberg, Nadine ^a   Warszawski, Josiane ^a   Meyer, Dominique ^a   Baruch, Dominique ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Extracellular matrix; Heparin; Platelet; Von Willebrand factor

Indexed keywords

DITHIOTHREITOL; HEPARIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD; CLASSIFICATION; DRUG EFFECT; HUMAN; KINETICS; METABOLISM; PROTEIN BINDING; VON WILLEBRAND DISEASE;

ANTIBODIES, MONOCLONAL; DITHIOTHREITOL; HEPARIN; HUMANS; IMMUNOGLOBULIN G; KINETICS; PROTEIN BINDING; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0034584410     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200026     Document Type: Article

References (41)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annual Review of Biochemistry 67: 395, 1998.
2. Sadler JE. A revised classification of von Willebrand disease. Thrombosis and Haemostasis 71: 520, 1994.
3. Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions. Thrombosis and Haemostasis 69: 177, 1993.
4. Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hilbert L, Ribba AS, Jorieux S, Mazurier C and the INSERM Network on Molecular abnormalities in von Willebrand disease. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. Thrombosis and Haemostasis 78: 451, 1997.
5. Pared FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III. Journal of Biological Chemistry 262: 13835, 1987.
6. Kalafatis M, Takahashi Y, Girma JP, Meyer D. Localization of a collagen-interactive domain of human von Willebrand factor between amino acid residue Gly 911 and Glu 1365. Blood 70: 1577, 1987.
7. Rand JH, Patel ND, Schwartz E, Zhou SL, Potter BJ. 150-kD von Willebrand factor binding protein extracted from human vascular subendothelium is type VI collagen. Journal of Clinical Investigation 88: 253, 1991.
8. Wise RJ, Lind SE, Handin RI. Detection of a bleeding disorder due to a defect in the binding of von Willebrand factor to collagen: A possible new inherited form of von Willebrand disease. Thrombosis and Haemostasis (Suppl) 389 (Abstract), 1997.
9. de Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu - evidence of the importance of the multimerization degree of vWF. Thrombosis and Haemostasis 69: 436, 1993.
10. Choay J, Petitou M, Lormeau JC, Synaï P, Casu B, Gatti G. Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochemical and Biophysical Research Communications 116: 492, 1983.
11. Badimon L, Badimon JJ, Rand J, Turitto V, Fuster VT. Platelet deposition on von Willebrand factor-deficient vessels: extracorporeal perfusion studies in swine with von Willebrand's disease using native and heparinized blood. Journal of Laboratory and Clinical Medicine 110: 634, 1987.
12. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. Journal of Clinical Investigation 87: 1787, 1991.
13. Sobel M, Bird KE, Tyler-Cross R, Marques D, Toma N, Conrad E, Harris RB. Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation 93: 992, 1996.
14. Fujimura Y, Titani K, Holland LZ, Roberts JR, Kostel P, Ruggeri ZM, Zimmerman TS. A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from aminoacid residue Val 449 to Lys 728. Journal of Biological Chemistry 262: 1734, 1987.
15. Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. Journal of Biological Chemistry 264: 17361, 1989.
16. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. Journal of Biological Chemistry 267: 8857, 1992.
17. Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA. Substructure of human von Willebrand factor. Proteolysis by V-8 and characterization of two functional domains. Journal of Biological Chemistry 261: 15679, 1986.
18. Kjellen L, Lindahl U. Proteoglycans: structure and interactions. Annual Review of Biochemistry 60: 443, 1991.
19. Denis C, Baruch D, Kielty CM, Ajzenberg N, Christophe O, Meyer D. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Arteriosclerosis and Thrombosis 13: 398, 1993.
20. Meyer D, Zimmerman TS, Obert B, Edgington TS. Hybridoma antibodies to von Willebrand factor. I. Characterization of seven clones. British Journal of Haematology 57: 597, 1984.
21. Piétu G, Ribba AS, Cherel G, Siguret V, Obert B, Rouault C, Ginsburg D, Meyer D. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. Thrombosis and Haemostasis 71: 788, 1994.
22. Baruch D, Denis C, Marteaux C, Schoevaert D, Coulombel L, Meyer D. Role of von Willebrand factor associated to extracellular matrices in platelet adhesion. Blood 77: 519, 1991.
23. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. A new variant of von Willebrand disease with defective binding to factor VIII. Blood 74: 1591, 1989.
24. Baruch D, Ajzenberg N, Denis C, Legendre P, Lormeau JC, Meyer D. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III. Thrombosis and Haemostasis 71: 141, 1994.
25. Schullek J, Jordan J, Montgomery RR. Interaction of von Willebrand factor with human platelets in the plasma milieu. Journal of Clinical Investigation 73: 421, 1984.
26. SAS Institute Inc. SAS/STAT User's Guide. Cary, NC, SAS Institute Inc., version 6, fourth edition, 2, 1989.
27. Scheffe H. The analysis of variance. New York, John Wiley & Sons Inc, 1959.
28. Veyradier A, Fressinaud E, Meyer D. Laboratory diagnosis of von Willebrand disease. International Journal of Clinical and Laboratory Research 28: 201, 1998.
29. Fischer BE, Kramer G, Mitterer A, Grillberger L, Reiter M, Mundt W, Dorner W, Eibl J. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation Factor VIII. Thrombosis Research 84: 55, 1996.
30. Randi AM, Jorieux S, Tuley EA, Mazurier C, Sadler JE. Recombinant von Willebrand disease mutation affects binding to glycoprotein Ib but not to collagen or heparin. Journal of Biological Chemistry 267: 21187, 1992.
31. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutations sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood; 91: 2032, 1998.
32. Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg 611 Cys and Arg 611 His) in the A1 loop responsible for type 2 von Willebrand disease with decreased platelet dependent function of von Willebrand factor. Blood 86: 1010, 1995,
33. Ribba AS, Hilbert L, Lavergne JM, Fressinaud E, Mazurier C, Meyer D and the INSERM network on molecular abnormalities in von Willebrand disease. Mutations at position 513, 552, 611 and 696 in the A1 loop of von Willebrand factor induce a type 2A phenotype. Usefulness of botrocetin to distinguish type 2A and 2M von Willebrand disease. Thrombosis and Haemostasis (Suppl) 510 (Abstract), 1999.
34. Castaman G, Eikenboom JCJ, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thrombosis and Haemostasis 82: 1065, 1999.
35. Fischer BE, Thomas KB, Dorner F. Collagen covalently immobilized onto plastic surfaces simplifies measurement of von Willebrand factor-collagen activity. Annals of Hematology 76: 159, 1998.
36. Casonato A, Pontara E, Bertomoro A, Zucchetto S, Zerbinati P, Girolami A. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers. Journal of Laboratory and Clinical Medicine 129: 251, 1997.
37. Depraetere H, Ajzenberg N, Girma GP, Lacombe C, Meyer D, Deckmyn H, Baruch D. Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor. Blood 91: 3792, 1998.
38. Perrault C, Ajzenberg N, Legendre P, Rastegar-Lari G, Meyer D, Lopez J, Baruch D. Modulation by heparin of the interaction of the A1 domain of von Willebrand factor with GPIb/IX. Blood 94: 4186, 1999.
39. Christophe O, Rouault C, Obert B, Piétu G, Meyer D, Girma GP. A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. British Journal of Haematology 90: 195, 1995.
40. Emsley J, Cruz M, Handin R, Liddington R. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. Journal of Biological Chemistry 273: 10396, 1998.
41. Celikel R, Varughese K, Madhusudan, Yoshioka A, Ware J, Ruggeri Z. Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nature Structural Biology 5: 189, 1998.